来立司琼
![]() | |
临床资料 | |
---|---|
其他名称 | F-0930-RS |
ATC码 |
|
识别信息 | |
| |
CAS号 | 143257-98-1 ![]() |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
化学信息 | |
化学式 | C18H20N4 |
摩尔质量 | 292.39 g·mol−1 |
|
来立司琼(INN:lerisetron;开发代号:F-0930-RS)是一种用作5-HT3受体拮抗剂的药物。[1]它是一种有效的止吐剂,[2][3]目前正在临床试验中用于治疗与癌症化疗相关的恶心。[4]
参考资料
- ^ Orjales A, Mosquera R, Labeaga L, Rodes R. New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation. Journal of Medicinal Chemistry. February 1997, 40 (4): 586–93. PMID 9046349. doi:10.1021/jm960442e.
- ^ Gomez-de-Segura IA, Grande AG, De Miguel E. Antiemetic effects of Lerisetron in radiation-induced emesis in the dog. Acta Oncologica. 1998, 37 (7–8): 759–63. PMID 10050999. doi:10.1080/028418698430160.
- ^ Cooper M, Sologuren A, Valiente R, Smith J. Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers. Arzneimittel-Forschung. 2002, 52 (9): 689–94. PMID 12404884. S2CID 24423582. doi:10.1055/s-0031-1299952.
- ^ Huckle R. Lerisetron. FAES. Current Opinion in Investigational Drugs. July 2003, 4 (7): 874–7. PMID 14619411.
![]() | 这是一篇与消化系统药相关小作品。您可以通过编辑或修订扩充其内容。 |